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Breast cancer is the second most common cancer in women and causes the death of 519,000 
people worldwide.  Many cancer genes are posttranscriptionally regulated by RNA-binding 
proteins (RBPs) and microRNAs. The RBP HuR binds to the AU-rich (ARE) regions of labile 
mRNAs, such as proto-oncogenes, stabilizing their mRNA and facilitating their translation into 
protein.  HuR has been described to control genes in multiple areas of the acquired capabilities 
model of cancer and has been hypothesized to be a tumor-maintenance gene, allowing for 
cancers to proliferate once they are established.  We investigated the role of HuR in aggressive 
and difficult to treat triple-negative breast cancer. MDA-MB-231 cells with higher levels of 
HuR had alterations in cell cycle kinetics and faster growth. Unexpectedly, HuR overexpression 
significantly interfered with tumor growth in orthotopic mouse models.  Tumors overexpressing 
HuR had fewer blood vessels and less apoptosis than the control tumors.  Microarray analysis 
revealed several genes overexpressed in the tumors with higher levels of HuR, including anti-
angiogenic TSP1 and TSP2.  Further analysis revealed TSP1 mRNA stability to be significantly 
increased in the cells overexpressing HuR.  Additionally, VEGFα was found to be downregulated 
at the mRNA and protein levels in the tumors overexpressing HuR.  Therefore, the putative 
mechanism seems to be an anti-angiogenetic effect by increasing expression of TSP1 but also 
surprisingly, down-regulating VEGFα, a target which HuR normally increases.  An approach of 
modulating HuR levels may overcome limitations associated with monotherapies targeting tumor 
vessel formation.
